William Roth, MD
Urology · Lafayette, LANPI 1215934187
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,028 of the $16,831 with a category attached, or 65.5%. It is spread thinly across 32 manufacturers, the largest accounting for just 21.8%. Reporting peaked in 2022 at $4,416 and has fallen 61.4% since, to $1,705 in 2025. Among urology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $47.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$4K
- Coloplast$4K
- Teleflex LLC$2K
- Medtronic$2K
- Neotract Inc.$1K
- AbbVie$864
- plus $3K from 26 others
Across 9 payments — averaging $2683.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teleflex LLC$24K
- Teleflex Medical Incorporated$297
What the payments were for
- Travel & lodging$5,65734%
- Food & beverage$11,02866%
- Education$1451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 32 | $3,662 |
| Coloplast | 61 | $3,559 |
| Teleflex LLC | 19 | $2,377 |
| Medtronic(2 entities) | 18 | $1,567 |
| Neotract Inc. | 12 | $1,438 |
| AbbVie(2 entities) | 50 | $864 |
| Astellas Pharma US Inc | 51 | $811 |
| Endo USA, Inc. | 16 | $432 |
| Boston Scientific | 14 | $342 |
| Calyxo, Inc. | 2 | $265 |
| Endo Pharmaceuticals Inc. | 9 | $215 |
| Antares Pharma, Inc. | 10 | $214 |
| Pfizer | 11 | $157 |
| Dendreon Pharmaceuticals LLC | 6 | $121 |
| Sumitomo Pharma America, Inc. | 7 | $120 |
| Myovant Sciences Inc. | 7 | $118 |
| Johnson & Johnson(2 entities) | 5 | $80 |
| Ferring Pharmaceuticals Inc. | 4 | $70 |
| Tolmar, Inc. | 3 | $53 |
| Laborie Medical Technologies Corp. | 1 | $53 |
| Zyla Life Sciences, Inc. | 3 | $49 |
| Blue Earth Diagnostics | 2 | $44 |
| Merck | 2 | $39 |
| Bayer | 2 | $35 |
| Dentsply IH Inc. | 2 | $28 |
| Cardiovascular Systems Inc. | 1 | $27 |
| Travere Therapeutics, Inc. | 1 | $22 |
| Accord Healthcare, Inc. | 1 | $20 |
| Intuitive Surgical | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $12 |
| Urogen Pharma, Inc. | 1 | $11 |
| Civco Medical Instruments | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$2,756
- Axonics$2,750
- TITAN$2,079
- Bulkamid$1,713
- INTERSTIM$1,021
- UroLift System$367
- XIAFLEX$249
- CVAC Aspiration System$179
How this compares
$16,831 in reported general payments places this provider in the 90th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiaflexCollagenase Clostridium Hist. | 24 | $315,566 |
| GemtesaVibegron | 210 | $131,385 |
| MyrbetriqMirabegron | 177 | $106,928 |
| XyostedTestosterone Enanthate | 53 | $34,777 |
| Tamsulosin Hcl | 1,174 | $12,651 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 398 | $12,644 |
| Testosterone Cypionate | 303 | $12,112 |
| ErtapenemErtapenem Sodium | 24 | $9,794 |
| Mirabegron ErMirabegron | 15 | $6,774 |
| Finasteride | 419 | $5,905 |
| Testosterone | 30 | $4,336 |
| Oxybutynin Chloride ErOxybutynin Chloride | 188 | $3,540 |
| Oxybutynin Chloride | 310 | $3,530 |
| Tolterodine Tartrate ErTolterodine Tartrate | 69 | $3,004 |
| Potassium Citrate ErPotassium Citrate | 57 | $2,603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Endo Pharmaceuticals Inc.Xiaflex | $215 | $315,56624 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $120 | $131,385210 claims |
| Astellas Pharma US IncMyrbetriq | $811 | $106,928177 claims |
| Antares Pharma, Inc.Xyosted | $214 | $34,77753 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 199 urology providers in Louisiana.
Other urology in Lafayette
- Jeffrey ThibodeauxLafayette$8K
- Thad BourqueLafayette$8K
- Christopher FontenotLafayette$6K
- Jeremy SpeegLafayette$6K
- Scott NeusetzerLafayette$6K
- Richard VanlangendonckNew Orleans$289K
- Gerard HenryBossier City$256K
- Ralph HendersonShreveport$211K
- Wayne HellstromNew Orleans$183K
- Colin GoudelockeNew Orleans$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.